Skip to main content
 CHANGE IN VISITATION GUIDELINES: Please read before visiting Rutgers Cancer Institute.

Print this page

EAY131: Molecular Analysis for Therapy Choice (MATCH)

Primary Objective

To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.

Secondary Objectives

1) To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas/multiple myeloma.

2) To evaluate time until death or disease progression.

3) To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, RNA, protein and imaging-based assessment platforms.

4) To assess whether radiomic phenotypes obtained from pre-treatment imaging and changes from pre- through post-therapy imaging can predict Objective Response and Progression Free Survival and to evaluate the association between pre-treatment radiomic phenotypes and targeted gene mutation patterns of tumor biopsy specimens.

Protocol Number: 171701
Phase: Phase II
Applicable Disease Sites: Any Site
Principal Investigator: Shridar Ganesan MD, PhD
Scope: National
Participating Institutions:
  • Rutgers Cancer Institute of New Jersey
  • RWJBarnabas Health
    • Monmouth Medical Center
    • Newark Beth Israel Medical Center
  • Trinitas Hospital and Comprehensive Cancer Center
Inclusion & Exclusion Criteria

Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

For further information about clinical trials, please contact us at 732-235-7356.